{"id":109568,"date":"2023-09-11T13:33:38","date_gmt":"2023-09-11T08:03:38","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=109568"},"modified":"2023-09-11T13:33:43","modified_gmt":"2023-09-11T08:03:43","slug":"indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/","title":{"rendered":"Indian pharmaceutical business to experience 8\u201310% sales growth this fiscal year: Crisil"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1725238527\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>According to a report, The Indian pharmaceuticals industry is expected to log in revenue growth of 8-10 per cent in the current fiscal aided by steady domestic growth and increased exports to regulated markets, even as semi-regulated markets face headwinds.<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-4192793672\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>Crisil said on Monday that a study of 186 drug makers, which accounted for about half of the Rs 3.7 lakh crore annual revenue of the sector last fiscal, indicates as much.<\/p><p>&#8220;Similar to last fiscal, domestic growth in fiscal 2024, will be led by 5-6 per cent increase in realisations, supported partly by high price hikes allowed by the National Pharmaceutical Pricing Authority (NPPA) for drugs under price regulation,&#8221; Crisil Research Director Aniket Dani said.<\/p><p>In addition, the sale of existing drugs and new launches will drive 3-4 per cent volume growth, he added.<\/p><div class=\"trade-content_5\" id=\"trade-2607036664\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>Operating profitability is also seen improving 50-100 basis points (bps) to 21 per cent this fiscal, supported by moderation in input and logistics costs, and abating pricing pressure in the US generics market, it said.<\/p><p>This comes after the margin shrank for two years in a row as a result of intense pricing pressure in the US and a sharp increase in input costs brought on by supply chain disruption during the Covid epidemic, Crisil noted.<\/p><p>Credit profiles will remain stable owing to low-leverage balance sheets and moderate capex plans, it stated.<\/p><p>Crisil said that, In the ongoing fiscal, domestic sales are expected to witness 8-10 per cent growth with the chronic segment expected to be the key contributor to revenues, because of the steady increase in lifestyle-related diseases and continued emphasis on health awareness, post the pandemic.<\/p><p>Formulation exports are seen up 7-9 per cent in rupee terms this fiscal, more driven by volumes, from new product launches, and abating price pressure in the US generics markets, it said.<\/p><p>On the other hand, an increase in claw-back taxes in select European markets could lead to lower growth in exports to Europe this fiscal, it added.<\/p><div class=\"trade-content-10\" id=\"trade-2536732086\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>&#8220;Growth in exports to Asia will improve this fiscal, after clocking a modest growth last fiscal, while exports to Africa will continue to remain sluggish on account of low forex reserves (impacting the purchasing power) and high currency volatility,&#8221; Crisil said.<\/p><p>Lower input prices and normalisation of supply chains should cull inventories to pre-pandemic levels, resulting in smaller incremental working capital debt this fiscal, it added.&nbsp;<\/p><p>Few Listed pharmaceutical companies in India<\/p><ul class=\"wp-block-list\"><li>Cipla<\/li>\n\n<li>Dr Redyy\u2019s Laboratories<\/li>\n\n<li>Sun Pharma<\/li>\n\n<li>Lupin Ltd<\/li>\n\n<li>Aurobindo Pharma<\/li><\/ul><div class=\"trade-after-content\" id=\"trade-4289220591\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>According to a report, The Indian pharmaceuticals industry is expected to log in revenue growth of 8-10 per cent in the current fiscal aided by steady domestic growth and increased exports to regulated markets, even as semi-regulated markets face headwinds. Crisil said on Monday that a study of 186 drug makers, which accounted for about [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":38157,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1696,31],"tags":[],"class_list":["post-109568","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-corporate-action","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Indian pharmaceutical business to experience 8\u201310% sales growth this fiscal year: Crisil - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"According to a report, The Indian pharmaceuticals industry is expected to log in revenue growth of 8-10 per cent in the current fiscal aided by steady domestic growth and increased exports to regulated markets, even as semi-regulated markets face headwinds.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Indian pharmaceutical business to experience 8\u201310% sales growth this fiscal year: Crisil\" \/>\n<meta property=\"og:description\" content=\"According to a report, The Indian pharmaceuticals industry is expected to log in revenue growth of 8-10 per cent in the current fiscal aided by steady domestic growth and increased exports to regulated markets, even as semi-regulated markets face headwinds.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-11T08:03:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-11T08:03:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/04\/CRISIL-Cover-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/\",\"url\":\"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/\",\"name\":\"Indian pharmaceutical business to experience 8\u201310% sales growth this fiscal year: Crisil - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/04\/CRISIL-Cover-Image.jpg\",\"datePublished\":\"2023-09-11T08:03:38+00:00\",\"dateModified\":\"2023-09-11T08:03:43+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"According to a report, The Indian pharmaceuticals industry is expected to log in revenue growth of 8-10 per cent in the current fiscal aided by steady domestic growth and increased exports to regulated markets, even as semi-regulated markets face headwinds.\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/04\/CRISIL-Cover-Image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/04\/CRISIL-Cover-Image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Indian pharmaceutical business to experience 8\u201310% sales growth this fiscal year: Crisil\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Indian pharmaceutical business to experience 8\u201310% sales growth this fiscal year: Crisil - Trade Brains Features","description":"According to a report, The Indian pharmaceuticals industry is expected to log in revenue growth of 8-10 per cent in the current fiscal aided by steady domestic growth and increased exports to regulated markets, even as semi-regulated markets face headwinds.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/","og_locale":"en_US","og_type":"article","og_title":"Indian pharmaceutical business to experience 8\u201310% sales growth this fiscal year: Crisil","og_description":"According to a report, The Indian pharmaceuticals industry is expected to log in revenue growth of 8-10 per cent in the current fiscal aided by steady domestic growth and increased exports to regulated markets, even as semi-regulated markets face headwinds.","og_url":"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2023-09-11T08:03:38+00:00","article_modified_time":"2023-09-11T08:03:43+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/04\/CRISIL-Cover-Image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/","url":"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/","name":"Indian pharmaceutical business to experience 8\u201310% sales growth this fiscal year: Crisil - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/04\/CRISIL-Cover-Image.jpg","datePublished":"2023-09-11T08:03:38+00:00","dateModified":"2023-09-11T08:03:43+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"According to a report, The Indian pharmaceuticals industry is expected to log in revenue growth of 8-10 per cent in the current fiscal aided by steady domestic growth and increased exports to regulated markets, even as semi-regulated markets face headwinds.","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/04\/CRISIL-Cover-Image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/04\/CRISIL-Cover-Image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/indian-pharmaceutical-business-to-experience-8-10-sales-growth-this-fiscal-year-crisil\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Indian pharmaceutical business to experience 8\u201310% sales growth this fiscal year: Crisil"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/109568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=109568"}],"version-history":[{"count":2,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/109568\/revisions"}],"predecessor-version":[{"id":109584,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/109568\/revisions\/109584"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/38157"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=109568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=109568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=109568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}